These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24501286)

  • 1. Fine-tuning the effects of T-cell therapy.
    Cancer Discov; 2014 Feb; 4(2):137. PubMed ID: 24501286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T cell therapy: 25years in the making.
    Gill S; Maus MV; Porter DL
    Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-killing CAR therapies gain speed.
    Weber M
    Cancer Discov; 2015 Jan; 5(1):7. PubMed ID: 25583785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
    Hombach AA; Abken H
    Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
    [No Abstract]   [Full Text] [Related]  

  • 6. Helping CAR T cells reach tumors.
    Cancer Discov; 2015 Jan; 5(1):OF6. PubMed ID: 25583818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.
    Chicaybam L; Bonamino MH
    Int Rev Immunol; 2014 Oct; 33(5):402-16. PubMed ID: 24911925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 10. First Chimeric Antigen Receptor T-Cell Therapy Approved.
    Brower V
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29106609
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell therapy targets glioblastoma.
    Cancer Discov; 2015 May; 5(5):458. PubMed ID: 25783861
    [No Abstract]   [Full Text] [Related]  

  • 13. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR diversity - a universal cancer immunotherapy biomarker?
    McNeel DG
    J Immunother Cancer; 2016; 4():69. PubMed ID: 27879971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next Steps in the CAR Journey of a Thousand Miles.
    Brenner MK
    Mol Ther; 2017 Oct; 25(10):2226-2227. PubMed ID: 28939089
    [No Abstract]   [Full Text] [Related]  

  • 16. Engineering T cells for cancer therapy.
    Mansoor W; Gilham DE; Thistlethwaite FC; Hawkins RE
    Br J Cancer; 2005 Nov; 93(10):1085-91. PubMed ID: 16251873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.
    Thistlethwaite F; Mansoor W; Gilham DE; Hawkins RE
    Curr Opin Mol Ther; 2005 Feb; 7(1):48-55. PubMed ID: 15732529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.
    Duong CP; Westwood JA; Berry LJ; Darcy PK; Kershaw MH
    Immunotherapy; 2011 Jan; 3(1):33-48. PubMed ID: 21174556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic approaches using genetically modified cells].
    Anliker B; Renner M; Schweizer M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1274-80. PubMed ID: 26349563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
    Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
    Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.